These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38909640)

  • 1. Investigation of selective glucocorticoid receptor modulation in high-grade serous ovarian cancer PDX models.
    Taya M; Hou X; Veneris JT; Kazi N; Larson MC; Maurer MJ; Heinzen EP; Chen H; Lastra R; Oberg AL; Weroha SJ; Fleming GF; Conzen SD
    J Gynecol Oncol; 2024 Jun; ():. PubMed ID: 38909640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
    Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
    Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer.
    Bennett L; Jaiswal PK; Harkless RV; Long TM; Gao N; Vandenburg B; Selman P; Durdana I; Lastra RR; Vander Griend D; Adelaiye-Ogala R; Szmulewitz RZ; Conzen SD
    Mol Cancer Ther; 2024 Apr; 23(4):552-563. PubMed ID: 38030378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
    Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
    Rob L; Cibula D; Knapp P; Mallmann P; Klat J; Minar L; Bartos P; Chovanec J; Valha P; Pluta M; Novotny Z; Spacek J; Melichar B; Kieszko D; Fucikova J; Hrnciarova T; Korolkiewicz RP; Hraska M; Bartunkova J; Spisek R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
    Cibula D; Rob L; Mallmann P; Knapp P; Klat J; Chovanec J; Minar L; Melichar B; Hein A; Kieszko D; Pluta M; Spacek J; Bartos P; Wimberger P; Madry R; Markowska J; Streb J; Valha P; Hassan HIB; Pecen L; Galluzzi L; Fucikova J; Hrnciarova T; Hraska M; Bartunkova J; Spisek R
    Gynecol Oncol; 2021 Sep; 162(3):652-660. PubMed ID: 34294416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
    Kach J; Long TM; Selman P; Tonsing-Carter EY; Bacalao MA; Lastra RR; de Wet L; Comiskey S; Gillard M; VanOpstall C; West DC; Chan WC; Griend DV; Conzen SD; Szmulewitz RZ
    Mol Cancer Ther; 2017 Aug; 16(8):1680-1692. PubMed ID: 28428441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.
    Harris FR; Zhang P; Yang L; Hou X; Leventakos K; Weroha SJ; Vasmatzis G; Kovtun IV
    Mol Oncol; 2019 Feb; 13(2):132-152. PubMed ID: 30499260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
    Ho GY; Vandenberg CJ; Lim R; Christie EL; Garsed DW; Lieschke E; Nesic K; Kondrashova O; Ratnayake G; Radke M; Penington JS; Carmagnac A; Heong V; Kyran EL; Zhang F; Traficante N; ; Huang R; Dobrovic A; Swisher EM; McNally O; Kee D; Wakefield MJ; Papenfuss AT; Bowtell DDL; Barker HE; Scott CL
    Ther Adv Med Oncol; 2023; 15():17588359231208674. PubMed ID: 38028140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer.
    Veneris JT; Huang L; Churpek JE; Conzen SD; Fleming GF
    Int J Gynecol Cancer; 2019 Feb; 29(2):357-364. PubMed ID: 30683758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
    Veneris JT; Darcy KM; Mhawech-Fauceglia P; Tian C; Lengyel E; Lastra RR; Pejovic T; Conzen SD; Fleming GF
    Gynecol Oncol; 2017 Jul; 146(1):153-160. PubMed ID: 28456378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
    Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
    Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis.
    Liu F; Zhang G; Lv S; Wen X; Liu P
    J Cell Biochem; 2019 Aug; 120(8):12618-12627. PubMed ID: 30834603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
    Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
    Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells.
    Thériault BL; Cybulska P; Shaw PA; Gallie BL; Bernardini MQ
    J Ovarian Res; 2014 Dec; 7():123. PubMed ID: 25528264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
    Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
    Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.
    Zervantonakis IK; Iavarone C; Chen HY; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis U; Leverson JD; Sampath D; Mills GB; Brugge JS
    Nat Commun; 2017 Aug; 8(1):365. PubMed ID: 28848242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
    Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
    Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.